CureVac (NASDAQ:CVAC) Sees Strong Trading Volume – What’s Next?

CureVac (NASDAQ:CVAC) saw unusually-high trading volume on Friday . Approximately 1,049,276 shares traded hands during trading, an increase of 29% from the previous session’s volume of 812,320 shares.The stock last traded at $3.00 and had previously closed at $2.80.

Analyst Upgrades and Downgrades

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $16.00 price objective on shares of CureVac in a research note on Friday, February 14th.

CureVac Stock Performance

The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The business’s fifty day moving average price is $3.40 and its two-hundred day moving average price is $3.19. The stock has a market capitalization of $675.00 million, a P/E ratio of 5.50 and a beta of 2.53.

Institutional Investors Weigh In On CureVac

Several institutional investors have recently modified their holdings of CVAC. Integrated Wealth Concepts LLC purchased a new stake in CureVac during the 3rd quarter valued at $35,000. Two Sigma Advisers LP bought a new stake in shares of CureVac in the 4th quarter worth about $48,000. Jump Financial LLC bought a new stake in shares of CureVac in the 4th quarter worth about $55,000. D. E. Shaw & Co. Inc. purchased a new stake in CureVac in the 4th quarter worth about $66,000. Finally, Barclays PLC bought a new stake in CureVac in the third quarter worth about $67,000. 17.26% of the stock is owned by institutional investors.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.